Skip to main content

OpenAI Bets Big on Cerebras with $2B Investment and Potential Stake

OpenAI's Strategic Bet on Cerebras

In what could become one of the most significant partnerships in AI infrastructure, OpenAI has committed over $20 billion to chip startup Cerebras for computing power over the next three years. The deal goes beyond simple procurement - OpenAI may acquire up to 10% equity in Cerebras, creating a strategic alignment between the two companies.

From Computing to Capital

The agreement builds on an existing relationship. Earlier this year, OpenAI signed a $10 billion deal for 750 megawatts of computing capacity from Cerebras. The new arrangement significantly expands this partnership, with OpenAI providing approximately $1 billion in funding to develop specialized data centers.

"This isn't just about buying chips," notes industry analyst Maria Chen. "OpenAI is effectively co-designing the infrastructure that will power its future AI models."

The Equity Angle

What makes this deal particularly interesting is the equity component. OpenAI will receive warrants that could give it a minority stake in Cerebras, with the percentage increasing based on spending levels. Sources suggest the stake could reach up to 10% of Cerebras shares. The company is expected to reveal details shortly, possibly as early as this Friday.

Cerebras' Road to IPO

For Cerebras, this partnership provides crucial validation as it prepares for a public offering. The company plans to go public in Q2 2024, preceded by a $3 billion funding round that would value it at $35 billion. Founded in 2015, Cerebras has made waves with its wafer-scale engine chips - technology so large that a single chip is about the size of a dinner plate.

Interestingly, OpenAI CEO Sam Altman was among Cerebras' early investors, adding another layer to this evolving relationship between the two companies.

The Bigger Picture

This massive investment underscores the insatiable demand for AI computing power, particularly for "inference" - the process of running trained AI models. As AI systems grow more complex, companies like OpenAI are racing to secure long-term infrastructure solutions rather than relying on piecemeal purchases.

"We're seeing the emergence of dedicated AI infrastructure ecosystems," explains tech strategist James Wu. "It's no longer just about buying GPUs - leading AI companies want vertically integrated solutions tailored to their specific needs."

Key Points:

  • $20B Commitment: OpenAI to spend over $20B on Cerebras computing power
  • Equity Potential: Could acquire up to 10% stake in Cerebras
  • IPO Preparation: Deal strengthens Cerebras ahead of planned public offering
  • Strategic Alignment: Builds on existing $10B computing agreement
  • Industry Trend: Highlights scramble for dedicated AI infrastructure

Enjoyed this article?

Subscribe to our newsletter for the latest AI news, product reviews, and project recommendations delivered to your inbox weekly.

Weekly digestFree foreverUnsubscribe anytime

Related Articles

News

Cerebras and OpenAI Strike $20 Billion AI Chip Deal Ahead of IPO

In a landmark deal, AI chipmaker Cerebras has secured a $2 billion agreement with OpenAI, marking one of the largest partnerships in the AI hardware space. The three-year contract includes a $1 billion investment from OpenAI for data center development and potential equity stakes. Meanwhile, Cerebras eyes a public listing that could value the company at over $35 billion, signaling growing investor confidence in specialized AI processors.

April 17, 2026
Artificial IntelligenceSemiconductorsTech IPOs
ChatGPT Hits 1 Billion Users as Women Take the Lead
News

ChatGPT Hits 1 Billion Users as Women Take the Lead

OpenAI's latest figures reveal a major shift in ChatGPT's user base - women now make up over half of its nearly 1 billion weekly active users. This marks a dramatic change from its early days when male users dominated at 80%. The AI platform's computing power is also set for massive expansion, expected to grow nearly tenfold by 2025 as adoption surges across demographics.

April 17, 2026
ChatGPTAI TrendsOpenAI
News

Alibaba-Backed AI Firm Doubles Funding as Partners Expand

Tongyi Yunqi, the company behind China's popular Tongyi Qianwen AI platform, just received a major capital boost. Its registered capital jumped from 100 million to 200 million yuan, with new investor Hangzhou Tongyi Lab joining existing backer Alibaba Cloud. The move signals continued confidence in the AI sector despite global market fluctuations.

April 17, 2026
Artificial IntelligenceAlibaba CloudChina Tech
ByteDance Seeks Top AI Talent in Global PhD Hunt
News

ByteDance Seeks Top AI Talent in Global PhD Hunt

TikTok's parent company ByteDance is rolling out an ambitious recruitment drive targeting PhD candidates worldwide. The program offers both full-time roles and internships across cutting-edge AI fields including large model applications and AI safety. Successful candidates will join teams in tech hubs from Beijing to San Diego, with priority given to researchers with notable publications or competition wins. This move signals ByteDance's continued push to lead in artificial intelligence innovation.

April 17, 2026
ByteDanceAI RecruitingPhD Opportunities
OpenAI's New AI Assistant Could Revolutionize Drug Discovery
News

OpenAI's New AI Assistant Could Revolutionize Drug Discovery

OpenAI has unveiled GPT-Rosalind, an AI model specifically designed for pharmaceutical and life sciences research. Named after DNA pioneer Rosalind Franklin, this tool promises to accelerate drug development by analyzing biochemical data and assisting with research tasks. Currently in limited release to select partners like Amgen and Moderna, the model shows remarkable potential in genomics and chemistry applications. This marks OpenAI's ambitious entry into scientific AI, directly competing with Google's DeepMind in transforming how medical research is conducted.

April 17, 2026
AI in healthcareDrug discoveryOpenAI
OpenAI Unveils GPT-Rosalind: AI That Could Revolutionize Drug Discovery
News

OpenAI Unveils GPT-Rosalind: AI That Could Revolutionize Drug Discovery

OpenAI has taken a bold step into life sciences with GPT-Rosalind, a specialized AI model named after DNA pioneer Rosalind Franklin. Unlike general chatbots, this tool can analyze protein structures, predict gene functions, and suggest experimental pathways—outperforming human experts in some tests. Currently available only to select biotech firms, it promises to accelerate drug development while raising important questions about AI's role in scientific discovery.

April 17, 2026
AI-in-biotechdrug-discoveryOpenAI